Recent Posts
- Garadacimab showing safety in HAE patients with long-term use
- HAE treatment Navenibart named EC orphan medicinal product
- Lack of first-line options in India impacts pediatric HAE treatment
- With rare diseases, not every cloud has a silver lining
- Intellia launches Phase 3 trial of gene-editing therapy NTLA-2002